Zusammenfassung
Entsprechend der Bedeutung von Pilzinfektionen der Haut und Schleimhäute werden fast 90% der Antimykotika als Lokaltherapeutika verordnet. Zur Behandlung von Organmykosen steht dagegen nur ein begrenztes medikamentöses Arsenal zur Verfügung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abeck D., Gruseck E., Korting H.C., Ring J. (1996): Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch. Ärztebl. 93: A2027–2032.
Amichai B., Grunwald M.H. (1998): Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole, and itraconazole. Int. J. Dermatol. 37: 410–415.
Arca E., Tastan H. B., Akar A., Kurumlu Z., Gur A.R. (2002): An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J. Dermatol. Treat. 13: 3–9.
Ariyaratnam S., Thakker N.S., Sloan P., Thornhill M.H. (1997): Potentiation of warfarin anticoagulant activity by miconazole oral gel. Brit. Med. J. 314: 349.
Bennett M.L., Fleischer A. B., Loveless J.W., Feldman S.R. (2000): Oral griseofulvin remains the treatment of choice for tinea capitis in children. Ped. Dermatol. 17: 304–309.
Bernhardt H. (1998): Pilze im Darm–Normalflora oder Erreger ? Z. ärztl. Fortbild. Qual. sich. (ZaeFQ) 92: 154–156.
Chu A.C. (1984): Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 169 (Suppl. 1): 81–86.
Crawford F., Hart R., Bell-Syer S., Torgerson D., Young P., Russell I. (2000): Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 1, 2000. Oxford: Update Software.
Dinnendahl V., Fricke U. (Hrsg.) (2002): Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe. Stammlieferung 1982 mit 1. bis 17. Ergänzungslieferung 2002, Govi-Verlag, Eschborn.
Evans E.G.V., Sigurgeirsson B. for the LION study group (1999): Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit. Med. J. 318: 1031–1035.
Friedlander S.F., Suarez S. (1998): Pediatric antifungal therapy. Ped. Dermatol. 16: 527–537.
Friedlander S.F. (2000): The optimal therapy for tinea capitis. Ped. Dermatol. 17: 325–326.
Goa K.L., Barradell L. B. (1995): Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.
Grant S.M., Clissold S.P. (1989): Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344.
Grant S.M., Clissold S.P. (1990): Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916.
Gupta A.K. (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J. Am. Podiatr. Med. Assoc. 92: 272–286.
Gupta A.K., Sauder D.N., Shear N.H. (1994): Antifungal agents: An overview. Part I+II. J. Am. Acad. Dermatol. 30: 677–698 und 911–933.
Gupta A.K., Gonder J.R., Shear N.H., Dilworth G.R. (1996): The development of green vision in association with terbinafine therapy. Arch. Dermatol. 132: 845–846.
Gupta A.K., Einarson T.R., Summerbell R.C., Shear N.H. (1998): An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 55: 645–674.
Gupta A.K., Shear N.H. (1999): The new oral antifungal agents for onychomycosis of the toenails. J. Eur. Acad. Dermatol. Venereol. 13: 1–13.
Gupta A.K., Lynde C.W., Konnikov N. (2001a): Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 44: 485–491.
Gupta A.K., Lambert J., Revuz J., Shear N. (2001b): Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur. J. Dermatol. 11: 6–10.
Haneke E., Tausch I., Bräutigam M., Weidinger G., Welzel D. (1995): Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J. Am. Acad. Dermatol. 32: 72–77.
Haria M., Bryson H.M. (1995): Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49: 103–120.
Haria M., Bryson H.M., Goa K.L. (1996): Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51: 585–620.
Hart R., Bell-Syer S.E.M., Crawford E, Torgerson D.J., Young P., Russell I. (1999): Systematic review of topical treatments for fungal infections of the skin and nails of the feet. Brit. Med. J. 319: 79–82.
Havu V., Heikkila H., Kuokkanen K., Rantanen T., Saari S., Stubb S., Suhonen R., Turjanmaa K. (2000): A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br. J. Dermatol. 142: 97–102.
Hay R.J. (1992): Treatment of dermatomycoses and onychomycoses–state of the art. Clin. Exp. Dermatol. 17 (Suppl. 1): 2–5.
Hecker D. (1997): Current trends in onychomycosis therapy: A literature review. Mount Sinai J. Med. 64: 399–405.
Higgins E.M., Fuller L.C., Smith C.H. (2000): Guidelines for the management of tinea capitis. Br. J. Dermatol. 143: 53–58.
Hornstein O.P., Nürnberg E. (Hrsg.) (1985): Externe Therapie von Hautkrankheiten: Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart, New York, pp. 304–315.
Howard R.M., Frieden I.J. (1999): Dermatophyte infections in children. Adv. Pediatr. Infect. Dis. 14: 73–107.
Katsambas A., Rigopoulos D., Antoniou C., Zachari A., Fragouli E., Stratigos J. (1996): Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: A single-blind randomized clinical study. Int. J. Dermatol. 35: 667–668.
Kauffman C.A., Carver P.L. (1997): Antifungal agents in the 1990s. Current status and future development. Drugs 53: 539–549.
Knoke M. (1998): Pilze im Orointestinaltrakt und ihre wissenschaftlich begründete Stellung. Z. ärztl. Fortbild. Qual.sich. (ZaeFQ) 92: 157–162.
Korting H.C. (1995): Dermatotherapie. Springer-Verlag, Berlin, Heidelberg, New York.
Male O. (1981): Medizinische Mykologie für die Praxis. Georg Thieme Verlag, Stuttgart, New York.
McClellan K.J., Wiseman L.R., Markham A. (1999): Terbinafine. An update of its use in superficial mycoses. Drugs 58: 179–202.
Merk H.F. (1993): Antimykotika. Teil I und II. Hautarzt 44: 191–199 und 257–267.
Müller J. (1993): Besonderheiten von Pilz-Keimträgern als Dauerausscheider. Zbl. Hyg. 194: 162–172.
Niewerth M., Korting H.C. (1999): Management of onychomycoses. Drugs 58: 283–296.
Niewerth M., Korting H.C. (2000): The use of systemic antimycotics in dermatotherapy. Eur. J. Dermatol. 10: 155–160.
Pierard G.E., Arrese J.E., Pierard-Franchimont C. (1996): Treatment and prophylaxis of tinea infections. Drugs 52: 209–224.
Powderly W.G., Mayer K.H., Perfect J.R. (1999): Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retroviruses 15: 1405–1412.
Quintanar-Guerrero D., Ganem-Quintanar A., Tapia-Olguin P., Kaliar Y.N., Buri P. (1998): The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev. Ind. Pharm. 24: 685–690.
Ring J., Fröhlich H.H. (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 133–136 und 211–213.
Roberts D.T. (1994): Oral therapeutic agents in fungal nail disease. J. Am. Acad. Dermatol. 31: S78 - S81.
Rösch W. (1996): Pilze im Stuhl, Pilze im Darm–therapeutische Konsequenzen? Versicherungsmedizin 48: 215–217.
Schäfer-Korting M., Blechschmidt J. Korting H.C. (1996): Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 39: 329–339.
Scheurlen M. (1996): Pathogenität von Pilzen im Darm–Stand der Diskussion. Fortschr. Med. 114: 319–321.
Scholz H., Schwabe U. (Hrsg.) (2000): Taschenbuch der Arzneibehandlung. Angewandte Pharmakologie, 12. Aufl. Urban& Fischer München, Jena.
Seebacher C. (1996): Mykophobie–eine neue Krankheit? Mycoses 39 (Suppl. 1): 30–32.
Sigurgeirsson B., Olafsson J.H., Steinsson J. B., Paul C., Billstein S., Evans E.G.V. (2002): Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis. Arch. Dermatol. 138: 353–357.
Steigleder G.K. (1993): Therapie der Hautkrankheiten, 4. Aufl. Georg Thieme Verlag, Stuttgart, New York.
Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. (2000): Effects of the antifungal agents on oxidative drug metabolism. Clin. Pharmacokinet. 38: 111–180.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fricke, U. (2003). Antimykotika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2002. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-11173-4_15
Download citation
DOI: https://doi.org/10.1007/978-3-662-11173-4_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43624-9
Online ISBN: 978-3-662-11173-4
eBook Packages: Springer Book Archive